Passive_JJ Immunization_NN with_IN Neutralizing_NP Antibodies_VBZ Interrupts_NP the_DT Mouse_NP Mammary_NP Tumor_NP Virus_NP Life_NP Cycle_NP Mouse_NP mammary_JJ tumor_NN virus_NN (_( MMTV_NP )_) infects_VBZ the_DT host_NN via_IN mucosal_JJ surfaces_NNS and_CC exploits_VBZ the_DT host_NN immune_JJ system_NN for_IN systemic_JJ spread_NN and_CC chronic_JJ infection_NN ._SENT We_PP have_VBP tested_VBN a_DT neutralizing_VBG rat_NN monoclonal_NN antibody_NN specific_JJ for_IN the_DT retroviral_JJ envelope_NN glycoprotein_NN gp52_NN for_IN its_PP$ efficiency_NN in_IN preventing_VBG acute_JJ and_CC chronic_JJ mucosal_JJ and_CC systemic_JJ infection_NN ._SENT The_DT antibody_NN completely_RB inhibits_VBZ the_DT superantigen_NN response_NN and_CC chronic_JJ viral_JJ infection_NN following_VBG systemic_JJ or_CC nasal_JJ infection_NN ._SENT Surprisingly_RB however_RB ,_, the_DT antibody_NN only_RB partially_RB inhibits_VBZ the_DT early_JJ infection_NN of_IN antigen-presenting_JJ cells_NNS in_IN the_DT draining_VBG lymph_NN node_NN ._SENT Despite_IN this_DT initially_RB inefficient_JJ protection_NN from_IN infection_NN ,_, superantigen-specific_JJ B-_NP and_CC T-cell_NN responses_NNS and_CC systemic_JJ viral_JJ spread_NN are_VBP abolished_VBN ,_, leading_VBG to_TO complete_VB clearance_NN of_IN the_DT retroviral_JJ infection_NN and_CC hence_RB interruption_NN of_IN the_DT viral_JJ life_NN cycle_NN ._SENT In_IN conclusion_NN ,_, systemic_JJ neutralizing_VBG monoclonal_NN antibodies_NNS can_MD provide_VB an_DT efficient_JJ protection_NN against_IN chronic_JJ retroviral_JJ amplification_NN and_CC persistence_NN ._SENT The_DT retrovirus_NN mouse_NN mammary_JJ tumor_NN virus_NN (_( MMTV_NP )_) is_VBZ transmitted_VBN from_IN infected_JJ mothers_NNS to_TO offspring_NNS via_IN milk_NN during_IN the_DT first_JJ 2_CD weeks_NNS after_IN birth_NN ._SENT MMTV_NP targets_VBZ three_CD major_JJ cell_NN types_NNS for_IN infection_NN :_: dendritic_JJ cells_NNS (_( DC_NP )_) and_CC B_NP lymphocytes_NNS early_JJ in_IN infection_NN and_CC epithelial_JJ cells_NNS of_IN exocrine_JJ secretory_JJ organs_NNS later_RBR on_IN (_( for_IN a_DT review_NN see_VBP reference_NN )_) ._SENT Once_RB MMTV_NP has_VBZ crossed_VBN the_DT mucosa_NN it_PP infects_VBZ DC_NP and_CC B_NP cells_NNS in_IN the_DT Peyer_NP 's_POS patches_NNS (_( PP_NP )_) before_IN spreading_VBG to_TO peripheral_JJ organs_NNS ._SENT Chronic_JJ infection_NN of_IN the_DT mammary_JJ gland_NN leads_VBZ to_TO viral_JJ transmission_NN via_IN milk_NN and_CC to_TO mammary_JJ tumor_NN development_NN after_IN retroviral_JJ insertion_NN next_JJ to_TO proto-oncogenes_NNS ._SENT Adult_NN mice_NNS can_MD be_VB chronically_RB infected_VBN by_IN subcutaneous_JJ (_( s.c._JJ )_) injection_NN or_CC by_IN nasal_JJ administration_NN of_IN the_DT virus_NN ._SENT After_IN entry_NN into_IN the_DT cell_NN ,_, viral_JJ RNA_NP is_VBZ reverse_RB transcribed_VBN and_CC the_DT resulting_VBG viral_JJ DNA_NN is_VBZ integrated_VBN into_IN the_DT genome_NN in_IN target_NN DC_NP and_CC B_NP cells_NNS ._SENT This_DT leads_VBZ to_TO expression_NN of_IN a_DT viral_JJ superantigen_NN (_( SAg_NP )_) at_IN the_DT cell_NN surface_NN ._SENT Oral_JJ ,_, s.c._JJ ,_, and_CC nasal_JJ routes_NNS of_IN infection_NN proceed_VB with_IN similar_JJ kinetics_NNS ,_, which_WDT are_VBP dominated_VBN by_IN efficient_JJ priming_NN of_IN a_DT SAg_NP T-cell_NN response_NN via_IN an_DT interaction_NN between_IN infected_JJ B_NP cells_NNS and_CC DC-primed_JJ SAg-reactive_JJ cognate_JJ T_NN cells_NNS ._SENT SAg-activated_JJ T_NN cells_NNS are_VBP slowly_RB deleted_VBN from_IN the_DT peripheral_JJ T-cell_NN repertoire_NN ._SENT This_DT deletion_NN represents_VBZ one_CD of_IN the_DT most_RBS sensitive_JJ readouts_NNS for_IN chronic_JJ infection_NN and_CC systemic_JJ spread_NN of_IN MMTV_NP ._SENT While_IN the_DT virus_NN persists_VBZ in_IN all_DT lymphoid_JJ and_CC nonlymphoid_JJ organs_NNS ,_, MMTV_NP establishes_VBZ a_DT chronic_JJ immune_JJ response_NN with_IN germinal_JJ centers_NNS ,_, persisting_VBG antigen_NN (_( Ag_NP )_) ,_, and_CC virus-specific_JJ B_NN and_CC T_NN cells_NNS only_RB in_IN the_DT draining_VBG lymph_NN node_NN (_( LN_NP )_) ._SENT This_DT leads_VBZ to_TO a_DT weak_JJ life-long_JJ neutralizing_VBG antibody_NN (_( Ab_NP )_) response_NN against_IN the_DT viral_JJ envelope_NN (_( Env_NP )_) protein_NN gp52_NN ._SENT Although_IN in_IN susceptible_JJ mice_NNS this_DT chronic_JJ Ab_NP response_NN is_VBZ unable_JJ to_TO clear_VB the_DT virus_NN infection_NN ,_, resistant_JJ mouse_NN strains_NNS such_JJ as_IN I/LnJ_NP have_VBP evolved_VBN a_DT strong_JJ neutralizing_VBG Ab_NP response_NN that_WDT controls_VBZ chronic_JJ infection_NN and_CC prevents_VBZ infection_NN of_IN the_DT progeny_NN ._SENT This_DT is_VBZ in_IN agreement_NN with_IN the_DT role_NN of_IN a_DT strong_JJ neutralizing_VBG antibody_NN response_NN in_IN interruption_NN of_IN the_DT viral_JJ life_NN cycle_NN ._SENT Since_IN the_DT early_JJ steps_NNS of_IN MMTV_NP infection_NN at_IN mucosal_JJ sites_NNS are_VBP very_RB similar_JJ to_TO those_DT of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD infection_NN and_CC because_IN sensitive_JJ assays_NNS allow_VBP monitoring_VBG of_IN the_DT early_JJ host_NN response_NN ,_, MMTV_NP is_VBZ considered_VBN an_DT ideal_JJ animal_NN model_NN with_IN which_WDT vaccine_NN strategies_NNS to_TO block_VB entry_NN and_CC spread_NN of_IN a_DT retrovirus_NN can_MD be_VB designed_VBN ._SENT Although_IN prior_JJ immunization_NN studies_NNS have_VBP shown_VBN evidence_NN for_IN the_DT role_NN of_IN a_DT humoral_JJ immune_JJ response_NN in_IN reduction_NN of_IN MMTV_NP infection_NN ,_, questions_NNS regarding_VBG the_DT in_IN vivo_JJ role_NN of_IN passive_JJ transfer_NN of_IN neutralizing_VBG Abs_NP in_IN the_DT protection_NN of_IN peripheral_JJ and_CC mucosal_JJ entry_NN sites_NNS of_IN viral_JJ infection_NN are_VBP unanswered_JJ ._SENT For_IN example_NN ,_, both_CC mucosal_JJ secretory_JJ immunoglobulin_NN A_NP (_( IgA_NP )_) and_CC systemic_JJ IgG_NP have_VBP been_VBN shown_VBN to_TO counteract_VB viral_JJ challenge_NN at_IN mucosal_JJ surfaces_NNS ._SENT However_RB it_PP is_VBZ unclear_JJ whether_IN passively_RB transferred_VBN systemic_JJ IgG_NP is_VBZ effective_JJ in_IN preventing_VBG mucosal_JJ virus_NN infection_NN ._SENT We_PP have_VBP recently_RB demonstrated_VBN that_DT induction_NN of_IN strong_JJ neutralizing_VBG Ab_NP responses_NNS after_IN virus_NN infection_NN did_VBD not_RB influence_VB infection_NN of_IN peripheral_JJ lymphoid_JJ organs_NNS but_CC strongly_RB inhibited_VBD mammary_JJ gland_NN infection_NN ,_, tumor_NN development_NN ,_, and_CC virus_NN transmission_NN to_TO the_DT next_JJ generation_NN ._SENT These_DT observations_NNS raised_VBD the_DT question_NN of_IN whether_IN neutralizing_VBG Abs_NP were_VBD able_JJ to_TO prevent_VB virus_NN production_NN and_CC amplification_NN in_IN nonlymphoid_JJ tissue_NN rather_RB than_IN initial_JJ infection_NN of_IN B_NN and_CC T_NN lymphocytes_NNS and_CC DC_NP ._SENT We_PP therefore_RB decided_VBD to_TO study_VB the_DT fate_NN of_IN MMTV_NP in_IN the_DT presence_NN of_IN preexisting_VBG neutralizing_VBG Abs_NP against_IN Env_NP proteins_NNS ._SENT To_TO do_VB this_DT ,_, we_PP succeeded_VBD in_IN generating_VBG a_DT neutralizing_VBG rat_NN monoclonal_NN Ab_NP (_( MAb_NP ;_: 2B3_JJ )_) against_IN the_DT viral_JJ major_JJ external_JJ Env_NP glycoprotein_NN (_( gp52_NN )_) ._SENT Our_PP$ data_NNS show_VBP that_IN a_DT single_JJ parenteral_JJ dose_NN of_IN MAb_NP 2B3_JJ can_MD efficiently_RB block_VB MMTV_NP SAg-induced_NP T-cell_NN responses_NNS as_RB well_RB as_IN the_DT appearance_NN of_IN viral_JJ particles_NNS in_IN the_DT milk_NN after_IN s.c._JJ or_CC mucosal_JJ challenge_NN with_IN MMTV_NP ._SENT Although_IN the_DT MAb_NP was_VBD unable_JJ to_TO prevent_VB virus_NN entry_NN into_IN draining_VBG LN_NP cells_NNS and_CC reverse_JJ transcription_NN in_IN the_DT first_JJ days_NNS after_IN s.c._JJ injection_NN ,_, MMTV_NP infection_NN was_VBD not_RB amplified_VBN by_IN the_DT SAg_NP response_NN and_CC was_VBD completely_RB cleared_VBN within_IN a_DT few_JJ days_NNS ._SENT These_DT data_NNS demonstrate_VBP a_DT virus_NN neutralization_NN pathway_NN that_WDT completely_RB inhibits_VBZ viral_JJ amplification_NN and_CC virus_NN spread_NN to_TO the_DT mammary_JJ gland_NN epithelium_NN but_CC that_WDT allows_VBZ viral_JJ uptake_NN ._SENT Animals_NNS and_CC immunization_NN ._SENT |_SYM BALB/c_NP mice_NNS and_CC Lewis_NP rats_NNS were_VBD purchased_VBN from_IN Harlan_NP Olac_NP (_( London_NP ,_, United_NP Kingdom_NP )_) ._SENT MMTV_NNS strain_VBP SW-infected_JJ mice_NNS were_VBD obtained_VBN from_IN IFFA_NP Credo_NP (_( L'Arlabesque_NP ,_, France_NP )_) and_CC bred_VBN in_IN the_DT Institut_NP Suisse_NP de_NP Recherche_NP sur_NP le_FW Cancer_NP animal_NN facilities_NNS ._SENT Adult_JJ female_JJ mice_NNS (_( 7_CD to_TO 10_CD weeks_NNS old_JJ )_) or_CC 7-day-old_JJ mice_NNS were_VBD used_VBN in_IN all_DT experiments_NNS ._SENT BALB/c_NN mice_NNS were_VBD passively_RB immunized_VBN by_IN intraperitoneal_JJ (_( i.p._JJ )_) injection_NN of_IN various_JJ doses_NNS of_IN purified_VBN MAbs_NNS or_CC phosphate-buffered_JJ saline_NN (_( PBS_NP )_) prior_RB to_TO or_CC after_IN MMTV_NP SW_NP infection_NN ._SENT The_DT concentration_NN of_IN rat_NN IgG_NP MAbs_NP in_IN the_DT serum_NN of_IN passively_RB immunized_VBN mice_NNS was_VBD assessed_VBN by_IN enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) ._SENT Abs_NP and_CC flow_NN cytometry_NN analysis_NN ._SENT |_SYM The_NP Abs_NP used_VBD in_IN this_DT study_NN included_VBD goat_NN anti-rat_NP IgG-Fcgamma-horseradish_NP peroxidase_NN (_( HRP_NP ;_: Jackson_NP Laboratory_NP ,_, Bar_NP Harbor_NP ,_, Maine_NP )_) ,_, rabbit_NN anti-rat_NP IgG_NP (_( Jackson_NP )_) ,_, rat_NN anti-mouse_NN CD29_NP MAb_NP (_( 9EG7_JJ ,_, IgG2a_NP ;_: Pharmingen_NP )_) ,_, polyclonal_JJ rabbit_NN anti-gp52_NP IgG_NP ,_, and_CC polyclonal_JJ sheep_NN anti-gp52_NP IgG_NP (_( kindly_RB provided_VBN by_IN P._NP Hainaut_NP ,_, University_NP of_IN Liege_NP ,_, Liege_NP ,_, Belgium_NP )_) and_CC an_DT HRP-conjugated_JJ donkey_NN anti-rabbit_NN Ab_NP (_( NA-934_NP ;_: Amersham_NP Life_NP Science_NP ,_, Little_NP Chalfont_NP ,_, United_NP Kingdom_NP )_) ._SENT Flow_NN cytometry_NN was_VBD performed_VBN by_IN using_VBG anti-Vbeta8.2-fluorescein_NN isothiocyanate_NN (_( FITC_NP ;_: F23.2_NP )_) ,_, anti-Vbeta6-FITC_NP (_( 44-22-1_CD )_) ,_, anti-B220-FITC_NP (_( RA3-6B2_NP ;_: BD_NP Pharmingen_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) or_CC Cy-Chrome_NP ,_, anti-CD11c-FITC_NP (_( HL3_NP ;_: BD_NP Pharmingen_NP )_) ,_, anti-CD11b-FITC_NP (_( M1/79_NP ;_: BD_NP Pharmingen_NP )_) ,_, F4/80-FITC_NP (_( BD_NP Pharmingen_NP )_) ,_, anti-CD4-phycoerythrin_NP (_( PE_NP )_) or_CC Cy-Chrome_NP (_( GK1.5_NP ;_: BD_NP Pharmingen_NP )_) ;_: anti-CD8-PE_NP (_( 53-6.7_CD ;_: BD_NP Pharmingen_NP )_) ,_, or_CC anti-major_NN histocompatibility_NN complex_JJ class_NN II_NP (_( MHC-II_NP ;_: I-A/I-E)-FITC_NP or_CC -PE_NP (_( M5/114_NP ;_: Boehringer_NP GmbH_NP ,_, Mannheim_NP ,_, Germany_NP )_) ._SENT The_DT antibodies_NNS recognizing_VBG murine_JJ CD138_NP (_( syndecan-1_NN and_CC 281-2_CD ;_: BD_NP Pharmingen_NP )_) and_CC F4/80_NP (_( BD_NP Pharmingen_NP )_) were_VBD biotinylated_JJ and_CC visualized_VBN with_IN streptavidin_NN conjugated_VBN to_TO Cy-Chrome_NP (_( BD_NP Pharmingen_NP )_) ._SENT Peripheral_JJ blood_NN lymphocytes_NNS (_( PBLs_NP )_) were_VBD isolated_VBN from_IN heparinized_JJ blood_NN samples_NNS by_IN centrifugation_NN through_IN a_DT Ficoll_NP (_( Pharmacia_NP ,_, Uppsala_NP ,_, Sweden_NP )_) cushion_NN ,_, and_CC the_DT layer_NN containing_VBG lymphocytes_NNS was_VBD collected_VBN ._SENT Mice_NNS were_VBD sacrificed_VBN ,_, LNs_NP and_CC spleens_NNS were_VBD isolated_VBN and_CC homogenized_VBN ,_, and_CC single-cell_NN suspensions_NNS were_VBD used_VBN ._SENT Lymphocytes_NNS were_VBD preincubated_VBN with_IN anti-FcgammaRII_NP MAb_NP (_( 2.4G2_JJ )_) whole_JJ supernatant_JJ and_CC stained_VBN in_IN one_CD step_NN with_IN FITC_NP ,_, PE_NP ,_, and_CC biotinylated_JJ or_CC Cy-Chrome-labeled_JJ MAbs_NNS as_RB described_VBD previously_RB ._SENT Dead_JJ cells_NNS were_VBD excluded_VBN from_IN acquisition_NN by_IN forward_JJ scatter_NN and_CC side_NN scatter_NN gating_VBG ._SENT Data_NNS were_VBD analyzed_VBN with_IN CELLQuest_NP software_NN (_( Becton_NP Dickinson_NP Immunocytometry_NP Systems_NP ,_, San_NP Jose_NP ,_, Calif._NP )_) ._SENT For_IN separation_NN of_IN B_NP cells_NNS ,_, T_NN cells_NNS ,_, DC_NP ,_, and_CC macrophages_NNS from_IN draining_VBG LNs_NP ,_, tissues_NNS were_VBD homogenized_VBN and_CC cells_NNS were_VBD stained_VBN with_IN either_DT anti-CD11b-FITC_NN ,_, anti-CD11c-FITC_NP ,_, or_CC anti-F4/80-FITC_NN ,_, together_RB with_IN anti-CD4-PE_NN ,_, anti-CD8-PE_NN ,_, and_CC B220-Cy-Chrome_NP MAbs_NP ._SENT T_NN cells_NNS were_VBD identified_VBN by_IN excluding_VBG cells_NNS positive_JJ for_IN CD11b_NP ,_, CD11c_NP ,_, F4/80_NP ,_, and_CC B220_NP and_CC gating_VBG on_IN CD4+_NP and_CC CD8+_NP cells_NNS ._SENT B_NP cells_NNS were_VBD identified_VBN as_IN CD11b-_NP CD11c-_NP F4/80-_NP CD4-_NP CD8-_NP B220+_NP cells_NNS ._SENT For_IN separation_NN of_IN macrophages_NNS and_CC DC_NP ,_, cells_NNS were_VBD stained_VBN with_IN a_DT combination_NN of_IN CD11c-FITC_NP ,_, syndecan-PE_NN ,_, CD19-PE_NP ,_, CD3-PE_NP ,_, and_CC F4/80-biotin_NP ,_, followed_VBN by_IN streptavidin-Cy-Chrome_NN ._SENT Macrophages_NNS were_VBD syndecan-_JJ CD11c-_NP CD19-_NP CD3-_NP F4/80+_NP ,_, and_CC DC_NP were_VBD syndecan-_JJ CD19-_NP CD3-_NP F4/80-_NP CD11c+_NP ._SENT Virus_NN isolation_NN and_CC infection_NN ._SENT |_SYM Milk_NN containing_VBG MMTV_NP SW_NP was_VBD obtained_VBN from_IN lactating_VBG virus-infected_JJ mothers_NNS ._SENT The_DT pool_NN of_IN infected_JJ milk_NN was_VBD diluted_VBN 1:3_CD in_IN PBS_NP and_CC centrifuged_VBN at_IN 600_CD x_NN g_NN for_IN 10_CD min_NN to_TO remove_VB cells_NNS and_CC to_TO skim_VB as_RB previously_RB described_VBN ._SENT Aliquots_NNS were_VBD stored_VBN at_IN -70C_NN ._SENT For_IN generation_NN of_IN MAbs_NNS in_IN rats_NNS ,_, viral_JJ particles_NNS of_IN MMTV_NP SW_NP were_VBD purified_VBN from_IN infected_JJ milk_NN ._SENT Briefly_RB ,_, MMTV-infected_JJ milk_NN was_VBD placed_VBN on_IN a_DT linear_JJ 20_CD to_TO 60_CD %_NN sucrose_NN gradient_NN and_CC ultracentrifuged_JJ for_IN 2_CD h_NN at_IN 95,000_CD x_NN g_NN and_CC 4C_JJ in_IN a_DT T11170_NP rotor_NN (_( Centrikon_NP )_) ._SENT The_DT fraction_NN between_IN the_DT 40_CD and_CC 20_CD %_NN sucrose_NN solutions_NNS was_VBD isolated_VBN ,_, diluted_VBN in_IN PBS_NP ,_, and_CC centrifuged_VBD for_IN 2_CD h_NN at_IN 95,000_CD x_NN g_NN and_CC 4C_JJ ._SENT The_DT virus_NN pellet_NN was_VBD dissolved_VBN in_IN PBS_NP ,_, and_CC the_DT protein_NN concentration_NN was_VBD determined_VBN by_IN using_VBG the_DT Bio-Rad_NP AG_NP (_( Reinach_NP ,_, Switzerland_NP )_) protein_NN assay_NN ._SENT Purified_VBN virus_NN (_( 1_CD mg/ml_NN )_) was_VBD aliquoted_VBN and_CC stored_VBN at_IN -70C_NN ._SENT For_IN all_DT s.c._NP infections_NNS 20_CD mul_NN of_IN diluted_JJ milk_NN containing_VBG approximately_RB 4_CD x_SYM 109_CD MMTV_NP SW_NP particles_NNS was_VBD injected_VBN into_IN the_DT footpads_NNS of_IN mice_NNS ._SENT After_IN 4_CD days_NNS mice_NNS were_VBD sacrificed_VBN and_CC the_DT draining_VBG popliteal_JJ LNs_NNS were_VBD removed_VBN ._SENT For_IN nasal_JJ infection_NN ,_, adult_NN mice_NNS were_VBD anesthetized_VBN by_IN injecting_VBG a_DT mixture_NN of_IN 1.5_CD mg_NN of_IN ketamine_NN (_( Ketasol_NP ;_: E._NP Graub_NP ,_, Bern_NP ,_, Switzerland_NP )_) and_CC 0.35_CD mg_NN of_IN xylazine_NN (_( Rompun_NP ;_: Bayer_NP ,_, Zurich_NP ,_, Switzerland_NP )_) ._SENT Subsequently_RB ,_, 1010_CD MMTV_NP SW_NP particles_NNS were_VBD administered_VBN to_TO each_DT nostril_NN ._SENT Six_CD days_NNS after_IN infection_NN ,_, the_DT nasally_RB associated_VBN lymphoid_JJ tissue_NN (_( NALT_NP )_) lymphocytes_NNS were_VBD isolated_VBN as_IN described_VBN previously_RB ._SENT For_IN infection_NN of_IN suckling_VBG mice_NNS 7-day-old_JJ BALB/c_NP mice_NNS were_VBD foster_JJ nursed_VBD by_IN MMTV_NP SW-infected_NP mothers_NNS ._SENT Production_NN of_IN virus-specific_JJ MAbs_NNS ._SENT |_SYM Eight-week-old_NP female_JJ Lewis_NP rats_NNS received_VBD one_CD s.c._NN injection_NN and_CC one_CD intramuscular_JJ injection_NN of_IN 30_CD mug_NN of_IN purified_VBN MMTV_NP SW_NP diluted_VBD on_IN a_DT volume_NN basis_NN in_IN complete_JJ Freund_NP 's_POS adjuvant_NN into_IN the_DT base_NN of_IN the_DT tail_NN followed_VBN by_IN three_CD injections_NNS of_IN 15_CD mug_NN of_IN purified_VBN MMTV_NP SW_NP mixed_VBD on_IN a_DT volume_NN basis_NN in_IN incomplete_JJ Freund_NP 's_POS adjuvant_NN every_DT 3_CD days_NNS ._SENT Inguinal_JJ and_CC para-aortic_JJ LNs_NPS were_VBD removed_VBN at_IN day_NN 12_CD ,_, and_CC lymphocytes_NNS were_VBD fused_VBN with_IN the_DT myeloma_NN cell_NN lines_NNS (_( NS1_NP )_) by_IN following_VBG standard_JJ protocols_NNS ._SENT Cells_NNS were_VBD cultured_VBN in_IN the_DT presence_NN of_IN hypoxanthine-aminopterin-thymidine-selective_JJ medium_NN ._SENT Supernatants_NNS were_VBD tested_VBN for_IN the_DT presence_NN of_IN virus_NN Env-specific_NP Abs_NP by_IN ELISA_NP ._SENT The_DT Ab_NP isotype_NN was_VBD determined_VBN by_IN using_VBG an_DT isotyping_JJ kit_NN (_( RMT_NP RC1_NP ;_: Serotec_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS recommendations_NNS ._SENT Abs_NP were_VBD affinity_NN purified_VBN on_IN protein_NN G-Sepharose_NP 4_CD Fast_NP Flow_NP columns_NNS (_( Pharmacia_NP )_) ,_, and_CC purity_NN was_VBD monitored_VBN by_IN sodium_NN dodecyl_NN sulfate-8_NN %_NN polyacrylamide_NN gel_NN electrophoresis_NN (_( SDS-8_NP %_NN PAGE_NN )_) ._SENT The_DT protein_NN concentration_NN was_VBD determined_VBN by_IN measuring_VBG UV_NP absorbance_NN at_IN 280_CD nm_NN ._SENT Immunoprecipitation_NN and_CC Western_JJ blotting_VBG ._SENT |_SYM One_CD hundred_CD microliters_NNS of_IN hybridoma_NN supernatant_JJ was_VBD incubated_VBN with_IN 20_CD mul_NN of_IN MMTV-containing_NP milk_NN for_IN 1_CD h_NN at_IN 4C_JJ ,_, followed_VBN by_IN incubation_NN for_IN 1_CD h_NN at_IN 4C_JJ with_IN a_DT mouse_NN anti-rat_NN kappa_NN chain_NN MAb_NP (_( MAR_NP 18.5_CD ;_: ATCC_NP TIB_NP 216_CD )_) linked_VBN to_TO protein_NN A-Sepharose_NP (_( Pharmacia_NP )_) ._SENT Samples_NNS were_VBD centrifuged_VBN at_IN 10,000_CD x_NN g_NN for_IN 15_CD s_NNS at_IN 4C_JJ and_CC washed_VBN three_CD times_NNS with_IN 50_CD mM_NP Tris_NP (_( pH_NN 7.4)-150_NP mM_NP NaCl-5_NP mM_NP EDTA-1_NP %_NN Triton_NP X-100_NP ._SENT For_IN analysis_NN ,_, aliquots_NNS were_VBD denatured_VBN by_IN being_VBG boiled_VBN three_CD times_NNS in_IN SDS-PAGE_NP buffer_NN for_IN 5_CD min_NN ,_, fractionated_VBN by_IN SDS-8_NP %_NN PAGE_NN ,_, and_CC electrophoretically_RB transferred_VBN to_TO nitrocellulose_NN filters_NNS (_( Schleicher_NP and_CC Schuell_NP ;_: 0.2-mum_NN pore_NN size_NN )_) ._SENT Nitrocellulose_NN filters_NNS were_VBD immunostained_VBN by_IN using_VBG a_DT polyclonal_JJ rabbit_NN anti-gp52_NP IgG_NP (_( Hainaut_NP )_) ,_, followed_VBN by_IN an_DT HRP-conjugated_JJ donkey_NN anti-rabbit_NN Ab_NP ._SENT Ab_NP binding_NN was_VBD visualized_VBN by_IN incubation_NN with_IN HRP_NP substrate_NN (_( Amersham_NP )_) ._SENT Polyclonal_JJ goat_NN anti-gp52_NN serum_NN was_VBD used_VBN as_IN a_DT positive_JJ control_NN ._SENT ELISA_NP ._SENT |_SYM Ninety-six-well_NP plates_NNS (_( F96_NP Nunc_NP Maxisorp_NP ;_: Life_NP Technologies_NPS ,_, Basel_NP ,_, Switzerland_NP )_) were_VBD coated_VBN overnight_RB with_IN 200_CD ng_NNS of_IN purified_VBN MMTV_NP SW/ml_NP ._SENT Alternatively_RB ,_, coating_NN was_VBD performed_VBN with_IN rabbit_NN anti-rat_NP IgG_NP and_CC plates_NNS were_VBD blocked_VBN with_IN 5_CD %_NN of_IN nonfat_NN dry_JJ milk_NN (_( Rapilait_NP ,_, Sulgen_NP ,_, Switzerland_NP )_) in_IN PBS_NP containing_VBG Tween_NP 20_CD (_( 0.1_CD %_NN [_SYM vol/vol_NN ]_SYM )_) ._SENT After_IN incubation_NN of_IN the_DT hybridoma_NN supernatant_JJ on_IN the_DT coated_JJ plate_NN for_IN 2_CD h_NN at_IN 37C_JJ ,_, specific_JJ Abs_NP were_VBD detected_VBN with_IN phosphatase-conjugated_JJ goat_NN anti-rat_NP Fcgamma-IgG_NP and_CC left_VBN for_IN 1_CD h_NN at_IN 37C_JJ ._SENT The_DT reaction_NN was_VBD developed_VBN by_IN adding_VBG 50_CD mul_NN of_IN o-phenylenediamine_NN (_( P-1526_NP ;_: Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) and_CC stopped_VBN by_IN addition_NN of_IN 50_CD mul_NN of_IN 2_CD M_NP sulfuric_JJ acid_NN ._SENT The_DT absorbance_NN was_VBD read_VBN at_IN 492_CD nm_NN with_IN Spectra_NP Count_NP (_( Meriden_NP )_) ._SENT In_IN vivo_JJ neutralization_NN assay_NN ._SENT |_SYM Sera_NP were_VBD collected_VBN by_IN tail_JJ bleeding_NN of_IN immunized_VBN mice_NNS and_CC depleted_VBN of_IN complement_NN by_IN heating_NN for_IN 30_CD min_NN at_IN 56C_NP ._SENT Sera_NP were_VBD mixed_VBN with_IN MMTV_NP and_CC PBS_NP in_IN equal_JJ amounts_NNS (_( final_JJ serum_NN concentration_NN :_: 1:3_LS )_) and_CC incubated_VBN on_IN ice_NN for_IN 1_CD h._NNS The_DT mixture_NN was_VBD s.c._RB injected_VBN into_IN the_DT hind_JJ footpads_NNS of_IN BALB/c_NP mice_NNS ,_, and_CC after_IN 4_CD days_NNS the_DT popliteal_JJ LNs_NP were_VBD removed_VBN ._SENT Cells_NNS were_VBD stained_VBN with_IN anti-Vbeta6-FITC_NN or_CC -Vbeta8.2-FITC_NN and_CC anti-CD4-PE_NN and_CC analyzed_VBD by_IN flow_NN cytometry_NN ._SENT PCR_NP ._SENT |_SYM DNA_NN extracted_VBN from_IN cells_NNS of_IN different_JJ origins_NNS was_VBD analyzed_VBN by_IN PCR_NP as_RB described_VBD previously_RB ._SENT In_IN brief_NN ,_, 50_CD ng_NNS of_IN DNA_NN isolated_VBN from_IN LNs_NP ,_, spleens_NNS ,_, and_CC mammary_JJ glands_NNS was_VBD analyzed_VBN by_IN PCR_NP with_IN specific_JJ primers_NNS for_IN exogenous_JJ MMTV_NP SW_NP ._SENT Primers_NNS for_IN Mtv-6_NP ,_, -8_CD ,_, and_CC -9_CD were_VBD used_VBN as_IN positive_JJ controls_NNS ._SENT To_TO semiquantify_VB the_DT number_NN of_IN MMTV_NP SW-infected_NP cells_NNS in_IN 105_CD total_JJ cells_NNS ,_, DNA_NP was_VBD extracted_VBN from_IN lymphocytes_NNS derived_VBN from_IN BALB.D2_NP mice_NNS containing_VBG two_CD copies_NNS of_IN the_DT endogenous_JJ provirus_NN Mtv-7_JJ ,_, which_WDT is_VBZ highly_RB homologous_JJ to_TO exogenous_JJ MMTV_NP SW_NP ,_, per_IN cell_NN ._SENT The_DT SAg_NP sequence_NN of_IN Mtv-7_JJ was_VBD amplified_VBN from_IN serial_JJ dilutions_NNS of_IN BALB.D2_NP DNA_NP into_IN BALB/c_NP DNA_NP ,_, keeping_VBG the_DT total_JJ DNA_NN concentration_NN constant_JJ ._SENT The_DT PCR_NP product_NN was_VBD detected_VBN by_IN liquid_JJ hybridization_NN with_IN a_DT radioactive_JJ oligonucleotide_NN probe_NN as_RB described_VBD previously_RB and_CC the_DT specific_JJ primer_NN 5'-CAA_NP GGA_NP GGT_NP CTA_NP GCT_NP CTG_NP GCG-3_NP '_POS ._SENT PCR_NP products_NNS were_VBD separated_VBN on_IN a_DT 6_CD %_NN denaturing_VBG polyacrylamide_NN gel_NN ,_, which_WDT was_VBD dried_VBN and_CC then_RB exposed_VBN to_TO X-Omat_NP film_NN (_( Eastman_NP Kodak_NP Company_NP ,_, Rochester_NP ,_, N.Y._NP )_) ._SENT Quantitative_JJ real-time_JJ PCR_NP ._SENT |_SYM Quantitative_NP PCR_NP was_VBD performed_VBN with_IN a_DT Light_NP Cycler_NP machine_NN and_CC a_DT FastStart_NP DNA_NP Master_NP SYBR_NP Green_NP I_NP kit_NN (_( Roche_NP ,_, Rotkreuz_NP Switzerland_NP )_) ._SENT Genomic_JJ DNA_NN of_IN samples_NNS and_CC controls_NNS was_VBD prepared_VBN by_IN standard_JJ proteinase_NN K_NN lysis_NN and_CC phenol-chloroform_NN extractions_NNS ._SENT The_DT positive_JJ control_NN consisted_VBN of_IN genomic_JJ DNA_NN of_IN spleen_NN cells_NNS isolated_VBN from_IN BALB/c_NP mice_NNS 6_CD months_NNS after_IN infection_NN with_IN MMTV_NP SW_NP ._SENT Naive_JJ BALB/c_NP mouse_NN DNA_NN was_VBD used_VBN as_IN a_DT negative_JJ control_NN ._SENT Quantification_NN of_IN integrated_JJ MMTV_NP SW_NP was_VBD based_VBN on_IN specific_JJ amplification_NN of_IN the_DT SAg_NP sequence_NN ._SENT Amplification_NN of_IN the_DT chromosome_NN sequence_NN D12Mit199_NP was_VBD used_VBN to_TO quantify_VB DNA_NN ._SENT The_DT primers_NNS were_VBD as_RB follows_VBZ :_: SW_NP forward_RB ,_, 5'-CTGCCATCCAAATCTTTGCT-3_JJ '_'' ;_: SW_NP reverse_NN ,_, 5'-ATGCATGCCACATATGTACACA-3_JJ '_'' ;_: D12Mit199_NP forward_RB ,_, 5'-CTGCCATCCAAATCTTTGCT-3_NP '_POS ,_, and_CC reverse_RB ,_, 5'-ATGCATGCCACATATGTACACA-3_NP '_POS ._SENT The_DT PCR_NP conditions_NNS for_IN cycling_NN were_VBD 5_CD s_NNS at_IN 95C_NN ,_, 20_CD s_NNS at_IN 65C_JJ ,_, and_CC 6_CD s_NNS at_IN 72C_NP for_IN 45_CD cycles_NNS in_IN a_DT 1x_NP master_NN mixture_NN containing_VBG 4_CD mM_NP MgCl2_NP ,_, 20_CD ng_NNS of_IN DNA_NP ,_, and_CC primers_NNS for_IN MMTV_NP SW_NP at_IN 0.25_CD muM_NN each_DT or_CC primers_NNS for_IN D12Mit199_NP at_IN 0.5_CD muM_NN each_DT ._SENT The_DT sensitivity_NN and_CC detection_NN limit_NN were_VBD assessed_VBN through_IN serial_JJ dilutions_NNS of_IN DNA_NP ._SENT Amplification_NN plots_NNS were_VBD analyzed_VBN by_IN the_DT second-derivative_JJ method_NN with_IN the_DT Light_NP Cycler_NP data_NNS analysis_NN ,_, version_NN 3.5_CD ,_, software_NN (_( Roche_NP )_) ._SENT Corrections_NNS for_IN amplification_NN efficiency_NN were_VBD included_VBN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Significant_JJ differences_NNS in_IN protection_NN were_VBD assessed_VBN by_IN the_DT Mann-Whitney_NP U_NP test_NN ;_: probability_NN (_( P_NN )_) values_VBZ <0.01_JJ were_VBD considered_VBN significant_JJ ._SENT Systemic_JJ neutralizing_VBG Abs_NP protect_VB peripheral_JJ and_CC mucosal_JJ lymphoid_JJ tissue_NN from_IN SAg_NP responses_NNS ._SENT |_SYM Env-reactive_NP MAbs_NP were_VBD obtained_VBN after_IN immunization_NN of_IN Lewis_NP rats_NNS with_IN purified_VBN infectious_JJ MMTV_NP SW_NP ._SENT We_PP selected_VBD the_DT IgG2a_NP and_CC kappa_NN chain_NN gp52-specific_JJ MAb_NP 2B3_JJ for_IN further_JJR studies_NNS ._SENT Two_CD antibodies_NNS (_( 4B8_JJ and_CC 10B9_JJ )_) from_IN the_DT same_JJ fusion_NN were_VBD used_VBN as_IN isotype-matched_JJ controls_NNS ._SENT To_TO test_VB whether_IN the_DT 2B3_JJ MAb_NP could_MD inhibit_VB MMTV_NP SW_NP infection_NN and_CC SAg-mediated_NP Vbeta6+_NP CD4+_NP T-cell_NN proliferation_NN in_IN vivo_RB ,_, BALB/c_NP mice_NNS were_VBD i.p._RB injected_VBN with_IN various_JJ doses_NNS of_IN MAb_NP 2B3_NP (_( 100_CD to_TO 0.1_CD mug_NN )_) ._SENT Five_CD hours_NNS later_JJR mice_NNS were_VBD challenged_VBN with_IN MMTV_NP s.c._NP by_IN injection_NN into_IN the_DT hind_JJ footpad_NN ._SENT After_IN 4_CD days_NNS the_DT mice_NNS were_VBD sacrificed_VBN ,_, the_DT draining_VBG popliteal_JJ LNs_NNS were_VBD removed_VBN ,_, and_CC the_DT percentage_NN of_IN Vbeta6+_NP CD4+_NP T_NN cells_NNS was_VBD determined_VBN by_IN flow_NN cytometry_NN ._SENT Control_NN mice_NNS which_WDT had_VBD been_VBN preinjected_VBN with_IN PBS_NP or_CC MAb_NP 4B8_NP had_VBD a_DT normal_JJ MMTV-induced_JJ stimulation_NN of_IN SAg-reactive_NP CD4+_NP Vbeta6+_NP T_NN cells_NNS of_IN from_IN 11_CD to_TO 24_CD %_NN ._SENT Three_CD micrograms_NNS of_IN MAb_NP 2B3_NP was_VBD able_JJ to_TO fully_RB block_VB the_DT SAg-reactive_JJ T-cell_NN response_NN ._SENT The_DT percentage_NN of_IN Vbeta8.2+_NP CD4+_NP T_NN cells_NNS (_( 14_CD %_NN )_) nonreactive_NN to_TO MMTV_NP SW_NP was_VBD not_RB affected_VBN by_IN MMTV_NP SW_NP infection_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Thus_RB ,_, i.p._JJ administration_NN of_IN MAb_NP 2B3_NP efficiently_RB prevented_VBD SAg-specific_JJ T-cell_NN responses_NNS in_IN the_DT draining_VBG popliteal_JJ LNs_NP ._SENT These_DT data_NNS suggest_VBP that_IN productive_JJ MMTV_NP infection_NN and_CC expression_NN of_IN viral_JJ SAg_NP by_IN the_DT host_NN cell_NN were_VBD aborted_VBN ._SENT We_PP studied_VBD whether_IN mucosa-associated_JJ lymphatic_JJ tissue_NN such_JJ as_IN NALT_NP was_VBD also_RB protected_VBN by_IN the_DT 2B3_JJ MAb_NP ._SENT Therefore_RB 3_CD or_CC 10_CD mug_NN of_IN MAb_NP 2B3_NP was_VBD i.p._RB injected_VBN into_IN adult_JJ BALB/c_NP mice_NNS and_CC 12_CD h_NN later_JJR mice_NNS were_VBD nasally_RB infected_VBN with_IN MMTV_NP SW_NP ._SENT Six_CD days_NNS after_IN nasal_JJ challenge_NN mice_NNS were_VBD sacrificed_VBN and_CC NALT_NP was_VBD isolated_VBN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT 2B3_JJ MAb_NP significantly_RB inhibited_VBD the_DT SAg-specific_NP Vbeta6+_NP CD4+_NP T-cell_NN response_NN ._SENT While_IN injection_NN of_IN 10_CD mug_NN completely_RB blocked_VBD the_DT Vbeta6+_NP CD4+_NP T-cell_NN increase_NN (_( 10.9_CD %_NN Vbeta6+_NP T_NN cells_NNS in_IN 2B3-treated_JJ infected_JJ mice_NNS and_CC 10.5_CD %_NN in_IN naive_JJ animals_NNS )_) ,_, protection_NN was_VBD incomplete_JJ with_IN 3_CD mug_NN (_( 11.8_CD %_NN )_) ._SENT Full_JJ protection_NN of_IN newborn_JJ mice_NNS fed_VBN by_IN MMTV_NP SW-infected_NP mothers_NNS was_VBD achieved_VBN only_RB when_WRB 100_CD mug_NN of_IN MAb_NP 2B3_NP was_VBD injected_VBN ._SENT This_DT indicates_VBZ that_IN a_DT 10-fold-higher_JJ dose_NN of_IN the_DT MAb_NP was_VBD required_VBN for_IN complete_JJ prevention_NN of_IN the_DT SAg_NP response_NN following_VBG intestinal_JJ mucosal_JJ infection_NN ._SENT Taken_VBN together_RB ,_, our_PP$ results_NNS indicate_VBP that_IN an_DT Env-specific_NP MAb_NP can_MD efficiently_RB neutralize_VB viral_JJ infection_NN at_IN both_DT s.c._JJ and_CC mucosal_JJ sites_NNS ._SENT Passive_JJ immunization_NN induces_VBZ long-lasting_JJ protection_NN ._SENT |_SYM To_TO evaluate_VB the_DT efficiency_NN and_CC duration_NN of_IN protection_NN conferred_VBN by_IN 10_CD mug_NN of_IN MAb_NP 2B3_NP (_( around_RB 1013_CD IgG_NP molecules_NNS )_) ,_, mice_NNS were_VBD challenged_VBN s.c._NN with_IN MMTV_NP SW_NP 5_CD h_NN and_CC 10_CD days_NNS after_IN passive_JJ i.p._JJ antibody_NN injection_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT SAg_NP stimulation_NN of_IN CD4+_NP Vbeta6+_NP T_NN cells_NNS was_VBD completely_RB inhibited_VBN even_RB when_WRB infection_NN occurred_VBD 10_CD days_NNS after_IN injection_NN of_IN MAbs_NP (_( 12_CD %_NN Vbeta6+_NP T_NN cells_NNS among_IN CD4+_NP T_NN cells_NNS )_) ._SENT The_DT rat_NN MAb_NN titers_NNS ,_, as_RB measured_VBN by_IN ELISA_NP ,_, in_IN the_DT serum_NN of_IN passively_RB immunized_VBN mice_NNS 5_CD h_NN after_IN i.p._JJ administration_NN of_IN 10_CD mug_NN of_IN MAbs_NP ranged_VBD from_IN 1.5_CD to_TO 3_CD mug/ml_NN ,_, and_CC titers_NNS varied_VBN between_IN 0.9_CD to_TO 1.5_CD mug/ml_NN at_IN day_NN 10_CD (_( data_NNS not_RB shown_VBN )_) ._SENT When_WRB MAb_NP 2B3_NP was_VBD injected_VBN 48_CD h_NN after_IN virus_NN injection_NN ,_, the_DT SAg_NP response_NN was_VBD normal_JJ ._SENT Injection_NN of_IN antibody_NN 24_CD h_NN after_IN virus_NN injection_NN showed_VBD a_DT partial_JJ inhibition_NN of_IN the_DT SAg_NP response_NN ._SENT These_DT results_NNS show_VBP that_IN once_RB infection_NN has_VBZ occurred_VBN no_DT effect_NN on_IN the_DT outcome_NN of_IN the_DT SAg_NP response_NN is_VBZ observed_VBN ,_, clearly_RB demonstrating_VBG that_IN the_DT neutralizing_VBG effect_NN occurred_VBN during_IN the_DT first_JJ phase_NN of_IN retroviral_JJ infection_NN ._SENT Passive_JJ immunization_NN interrupts_VBZ the_DT viral_JJ life_NN cycle_NN ._SENT |_SYM One_CD of_IN the_DT features_NNS of_IN MMTV_NP infection_NN is_VBZ the_DT peripheral_JJ clonal_JJ deletion_NN of_IN SAg-reactive_NP CD4+_NP T_NN cells_NNS ._SENT Deletion_NN of_IN SAg-reactive_JJ T_NN cells_NNS represents_VBZ the_DT most_RBS sensitive_JJ assay_NN available_JJ for_IN detection_NN of_IN chronic_JJ MMTV_NP infection_NN and_CC systemic_JJ spread_NN ._SENT To_TO assess_VB whether_IN this_DT deletion_NN is_VBZ inhibited_VBN by_IN MAb_NP 2B3_JJ ,_, female_JJ adult_NN mice_NNS were_VBD immunized_VBN i.p._JJ with_IN 100_CD mug_NN of_IN 2B3_JJ ,_, with_IN the_DT nonneutralizing_JJ MAb_NN 4B8_JJ ,_, or_CC with_IN PBS_NP (_( control_NN mice_NNS )_) ._SENT After_IN 12_CD h_NN groups_NNS of_IN three_CD to_TO five_CD mice_NNS were_VBD challenged_VBN either_RB by_IN s.c._JJ injection_NN into_IN the_DT hind_JJ footpad_NN or_CC by_IN nasal_JJ administration_NN of_IN MMTV_NP SW_NP ._SENT At_IN days_NNS 30_CD ,_, 90_CD ,_, and_CC 120_CD the_DT percentage_NN of_IN Vbeta6+_NP CD4+_NP T_NN lymphocytes_NNS in_IN the_DT blood_NN was_VBD determined_VBN ._SENT At_IN day_NN 90_CD after_IN s.c._JJ and_CC nasal_JJ infection_NN ,_, with_IN the_DT exception_NN of_IN 1_CD nasally_RB infected_JJ animal_NN ,_, all_DT control_NN mice_NNS (_( injected_VBN with_IN MAb_NP 4B8_NP or_CC PBS_NP )_) had_VBD deleted_VBN the_DT Vbeta6+_NP CD4+_NP T_NN cells_NNS (_( Fig._NN and_CC )_) ._SENT In_IN contrast_NN ,_, none_NN of_IN the_DT mice_NNS injected_VBN with_IN the_DT 2B3_JJ MAb_NP had_VBD deleted_VBN SAg-reactive_JJ T_NN cells_NNS even_RB after_IN 120_CD days_NNS ._SENT This_DT implies_VBZ that_IN chronic_JJ viral_JJ infection_NN is_VBZ inhibited_VBN in_IN mice_NNS passively_RB immunized_VBN with_IN a_DT single_JJ dose_NN of_IN systemic_JJ MAbs_NNS ._SENT To_TO test_VB whether_IN 2B3-treated_JJ mice_NNS could_MD transmit_VB the_DT virus_NN to_TO the_DT next_JJ generation_NN ,_, adult_JJ female_JJ mice_NNS were_VBD mated_VBN 12_CD to_TO 16_CD weeks_NNS after_IN infection_NN with_IN uninfected_JJ adult_JJ male_JJ mice_NNS ._SENT The_DT peripheral_JJ deletion_NN of_IN Vbeta6+_NP CD4+_NP T_NN cells_NNS in_IN the_DT PBLs_NNS of_IN newborn_JJ mice_NNS was_VBD assessed_VBN 4_CD to_TO 5_CD weeks_NNS after_IN birth_NN by_IN flow_NN cytometry_NN ._SENT In_IN the_DT parents_NNS no_DT deletion_NN was_VBD detected_VBN 210_CD to_TO 240_CD days_NNS after_IN passive_JJ immunization_NN with_IN 2B3_JJ ._SENT Three_CD consecutive_JJ litters_NNS (_( L1_JJ to_TO L3_NP )_) were_VBD analyzed_VBN since_IN viremia_NN can_MD be_VB increased_VBN after_IN consecutive_JJ lactations_NNS ._SENT None_NN of_IN the_DT offspring_NN from_IN MMTV-challenged_JJ mothers_NNS treated_VBN with_IN MAb_NP 2B3_JJ showed_VBD deletion_NN of_IN SAg-reactive_JJ T_NN cells_NNS ,_, in_IN contrast_NN to_TO control_NN mice_NNS (_( mice_NNS injected_VBN with_IN MAb_NP 4B8_NP or_CC PBS_NP )_) ._SENT This_DT lack_NN of_IN transmission_NN indicates_VBZ that_IN the_DT 2B3_JJ MAb_NN completely_RB blocks_VBZ chronic_JJ MMTV_NP SW_NP infection_NN after_IN s.c._JJ or_CC nasal_JJ application_NN of_IN the_DT virus_NN ._SENT MMTV_NP infection_NN is_VBZ not_RB productive_JJ after_IN passive_JJ immunization_NN ._SENT |_SYM The_DT capacity_NN of_IN MAb_NP 2B3_JJ to_TO inhibit_VB viral_JJ entry_NN and_CC reverse_JJ transcription_NN in_IN target_NN cells_NNS was_VBD tested_VBN by_IN injecting_VBG 100_CD mug_NN of_IN MAb_NP 2B3_JJ i.p._NN into_IN mice_NNS and_CC infecting_VBG them_PP 12_CD h_NN later_RBR with_IN MMTV_NP SW_NP injected_VBD into_IN the_DT hind_JJ footpad_NN ._SENT Two_CD or_CC 4_CD days_NNS later_RBR the_DT draining_NN popliteal_JJ LNs_NP were_VBD removed_VBN and_CC infection_NN was_VBD determined_VBN by_IN semiquantitative_JJ PCR_NP ._SENT In_IN control_NN mice_NNS viral_JJ DNA_NN was_VBD detected_VBN in_IN the_DT draining_VBG LNs_NP on_IN days_NNS 2_CD and_CC 4_CD after_IN challenge_NN ._SENT An_DT increase_NN in_IN numbers_NNS of_IN viral_JJ copies_NNS per_IN cell_NN was_VBD observed_VBN on_IN day_NN 4_CD ,_, when_WRB infected_JJ B_NP cells_NNS are_VBP preferentially_RB amplified_VBN with_IN SAg-mediated_JJ help_NN ._SENT In_IN 2B3-treated_JJ mice_NNS ,_, infection_NN of_IN the_DT draining_VBG LN_NP cells_NNS was_VBD clearly_RB detectable_JJ ._SENT Similar_JJ intensities_NNS were_VBD observed_VBN on_IN days_NNS 2_CD and_CC 4_CD after_IN injection_NN in_IN 2B3-treated_JJ mice_NNS ,_, confirming_VBG the_DT absence_NN of_IN a_DT preferential_JJ amplification_NN due_JJ to_TO SAg-mediated_JJ help_NN ._SENT Based_VBN on_IN amplification_NN of_IN the_DT highly_RB homologous_JJ endogenous_JJ Mtv-7_JJ sequence_NN in_IN serially_RB diluted_VBN BALB.D2_NP DNA_NP ,_, we_PP estimated_VBD that_IN the_DT early_JJ infection_NN was_VBD reduced_VBN about_IN 10-fold_NN by_IN the_DT MAb_NP 2B3_JJ treatment_NN ._SENT We_PP further_RBR assessed_VBD the_DT reduction_NN of_IN retroviral_JJ infection_NN by_IN treatment_NN with_IN MAb_NP 2B3_JJ using_VBG quantitative_JJ real-time_JJ PCR_NP specific_NN for_IN the_DT MMTV_NP SW_NP SAg_NP sequence_NN ._SENT Mice_NNS were_VBD injected_VBN with_IN the_DT MAb_NP and_CC infected_VBN as_IN previously_RB described_VBN ._SENT MMTV_NP SW_NP infection_NN of_IN B_NP cells_NNS ,_, T_NN cells_NNS ,_, DC_NP ,_, macrophages_NNS ,_, and_CC unsorted_JJ cells_NNS in_IN the_DT draining_VBG LN_NP ,_, which_WDT were_VBD purified_VBN by_IN fluorescence-activated_JJ cell_NN sorting_VBG ,_, was_VBD quantified_VBN on_IN day_NN 2_CD after_IN virus_NN injection_NN ._SENT On_IN day_NN 2_CD ,_, compared_VBN to_TO chronically_RB infected_JJ splenocytes_NNS ,_, B_NP cells_NNS and_CC DC_NP from_IN MMTV-injected_JJ control_NN mice_NNS showed_VBD 50-_CD to_TO 100-times-weaker_NP infection_NN ._SENT Viral_JJ DNA_NN was_VBD not_RB detected_VBN in_IN T_NN cells_NNS and_CC macrophages_NNS ._SENT All_PDT these_DT data_NNS are_VBP in_IN complete_JJ agreement_NN with_IN our_PP$ previously_RB published_VBN results_NNS ,_, indicating_VBG that_IN early_JJ infection_NN occurs_VBZ in_IN DC_NP and_CC B_NP cells_NNS at_IN very_RB low_JJ levels_NNS before_IN SAg-driven_NP viral_JJ amplification_NN ._SENT In_IN the_DT MAb-treated_JJ cells_NNS ,_, no_DT MMTV_NP SW_NP infection_NN was_VBD detected_VBN ._SENT The_DT sensitivity_NN of_IN this_DT quantitative_JJ PCR_NP is_VBZ limited_VBN for_IN the_DT following_VBG reasons_NNS :_: only_RB 20_CD ng_NNS of_IN genomic_JJ DNA_NN (_( 4,000_CD cells_NNS )_) per_IN real-time_JJ PCR_NP assay_NN was_VBD used_VBN ,_, and_CC the_DT observed_JJ detection_NN limit_NN corresponded_VBD to_TO 1_CD to_TO 3_CD copies_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT results_NNS show_VBP that_IN the_DT 2B3_JJ pretreatment_NN reduced_VBD the_DT early_JJ infection_NN in_IN B_NP cells_NNS and_CC DC_NP ._SENT Using_VBG the_DT more_RBR sensitive_JJ but_CC less_RBR quantitative_JJ semiquantitative_JJ PCR_NP we_PP found_VBD about_IN 10-fold_NN reductions_NNS in_IN infection_NN in_IN both_DT classical_JJ MMTV_NP targets_NNS ,_, DC_NP and_CC B_NP cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Therefore_RB ,_, the_DT tropism_NN of_IN MMTV_NP remained_VBD the_DT same_JJ in_IN the_DT presence_NN of_IN the_DT MAb_NP but_CC was_VBD reduced_VBN about_IN 10-fold_NN ._SENT Next_RB ,_, the_DT impact_NN of_IN the_DT 2B3_JJ pretreatment_NN on_IN chronic_JJ MMTV_NP SW_NP infection_NN was_VBD determined_VBN by_IN semiquantitative_JJ PCR_NP ._SENT Two_CD months_NNS after_IN infection_NN ,_, 2B3-pretreated_JJ mice_NNS had_VBD no_DT detectable_JJ infection_NN in_IN the_DT draining_VBG LN_NP ,_, nondraining_NP LNs_NP ,_, spleen_NN ,_, or_CC mammary_JJ gland_NN ._SENT Taken_VBN together_RB ,_, our_PP$ results_NNS demonstrate_VBP that_IN MAb_NP 2B3_NP does_VBZ not_RB prevent_VB initial_JJ reverse_JJ transcription_NN but_CC significantly_RB decreases_VBZ the_DT early_JJ infection_NN in_IN B_NP cells_NNS and_CC DC_NP ._SENT Therefore_RB both_DT SAg-driven_NP amplification_NN of_IN infected_JJ B_NP cells_NNS and_CC chronic_JJ infection_NN ,_, but_CC not_RB acute_JJ infection_NN ,_, are_VBP abolished_VBN in_IN the_DT presence_NN of_IN neutralizing_VBG antibodies_NNS ._SENT B-cell_NN differentiation_NN is_VBZ prevented_VBN by_IN Ab_NP treatment_NN ._SENT |_SYM During_IN the_DT SAg_NP response_NN ,_, infected_JJ B_NP cells_NNS differentiate_VBP to_TO plasmablasts_NNS with_IN SAg-mediated_JJ cognate-T-cell_NN help_NN ._SENT The_DT induced_VBN plasmablasts_NNS modulate_VBP the_DT B-cell_NN marker_NN CD45R_NP (_( B220R_NP )_) and_CC induce_VB expression_NN of_IN the_DT plasma_NN cell_NN marker_NN CD138_NP (_( syndecan-1_JJ )_) ._SENT As_IN shown_VBN in_IN Fig._NN the_DT induction_NN of_IN B-cell_NN differentiation_NN into_IN MHC-II+_NP B220low_NP plasmablast_NN B_NN cells_NNS is_VBZ completely_RB blocked_VBN in_IN 2B3-treated_JJ mice_NNS ._SENT Moreover_RB ,_, in_IN these_DT mice_NNS no_DT activation_NN and_CC CD138_JJ expression_NN of_IN MHC-II+_NP B220low_NP B_NP cells_NNS were_VBD observed_VBN and_CC amplification_NN of_IN SAg-reactive_NP Vbeta6+_NP CD4+_NP T_NN cells_NNS was_VBD lacking_VBG ._SENT These_DT results_NNS show_VBP that_IN the_DT MAb_NP 2B3_NP efficiently_RB blocks_VBZ SAg-mediated_NP B-_NP and_CC T-cell_NN activation_NN ._SENT Passive_JJ immunization_NN renders_VBZ mice_NNS susceptible_JJ to_TO superinfection_NN with_IN MMTV_NP SW_NP ._SENT |_SYM In_IN the_DT course_NN of_IN a_DT normal_JJ MMTV_NP infection_NN ,_, neutralizing_VBG Abs_NP that_IN completely_RB block_VB superinfection_NN with_IN a_DT second_JJ MMTV_NP isolate_NN are_VBP obtained_VBN ._SENT To_TO address_VB the_DT question_NN of_IN whether_IN 2B3-treated_JJ mice_NNS generate_VBP a_DT natural_JJ neutralizing_VBG Ab_NP response_NN ,_, mice_NNS were_VBD rechallenged_VBN with_IN MMTV_NP SW_NP 2_CD months_NNS after_IN the_DT initial_JJ MMTV_NP SW_NP infection_NN ._SENT As_IN shown_VBN in_IN Table_NP ,_, control_NN mice_NNS (_( first_JJ injection_NN :_: isotype-matched_JJ Ab_NP IgG2a_NP )_) could_MD easily_RB be_VB infected_VBN with_IN MMTV_NP SW_NP (_( second_JJ injection_NN )_) ,_, as_RB measured_VBN by_IN the_DT deletion_NN of_IN Vbeta6_NP T_NN cells_NNS ._SENT MMTV_NP SW-infected_NP mice_NNS deleted_VBN Vbeta6_NP T_NN cells_NNS after_IN the_DT first_JJ injection_NN and_CC did_VBD not_RB respond_VB to_TO a_DT second_JJ challenge_NN due_JJ to_TO the_DT presence_NN of_IN neutralizing_VBG Abs_NP ._SENT Mice_NNS treated_VBN with_IN MAb_NP 2B3_JJ did_VBD not_RB delete_VB Vbeta6_NP T_NN cells_NNS after_IN the_DT first_JJ MMTV_NP injection_NN but_CC did_VBD delete_VB them_PP after_IN the_DT second_JJ MMTV_NP challenge_NN ._SENT By_IN challenging_VBG mice_NNS with_IN another_DT MMTV_NP strain_NN (_( C4_NP )_) that_WDT is_VBZ cross-neutralized_VBN by_IN the_DT SW-specific_JJ neutralizing-Ab_NN response_NN ,_, we_PP obtained_VBD similar_JJ results_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT results_NNS demonstrate_VBP that_IN the_DT 2B3_JJ MAb_NP blocks_NNS not_RB only_RB SAg_NP presentation_NN and_CC T-cell_NN deletion_NN but_CC also_RB the_DT generation_NN of_IN long-lasting_JJ neutralizing_VBG Abs_NP ._SENT In_IN addition_NN ,_, the_DT 2B3_JJ MAb_NN was_VBD not_RB capable_JJ of_IN protecting_VBG mice_NNS from_IN MMTV_NP infection_NN 2_CD months_NNS after_IN passive_JJ immunization_NN ._SENT In_IN this_DT study_NN we_PP show_VBP that_IN a_DT neutralizing_VBG MAb_NN specific_JJ for_IN MMTV_NP Env_NP gp52_NN is_VBZ able_JJ to_TO completely_RB inhibit_VB retroviral_JJ spread_NN and_CC persistence_NN in_IN lymphoid_JJ and_CC nonlymphoid_JJ organs_NNS ._SENT In_IN the_DT presence_NN of_IN the_DT Ab_NP ,_, however_RB ,_, complete_JJ protection_NN from_IN infection_NN is_VBZ not_RB observed_VBN in_IN the_DT natural_JJ targets_NNS for_IN MMTV_NP ,_, B_NP cells_NNS and_CC DC_NP ._SENT Despite_IN the_DT approximately_RB 10-fold-reduced_JJ ,_, albeit_IN clearly_RB detectable_JJ ,_, infection_NN ,_, no_DT SAg-mediated_JJ amplification_NN of_IN infected_JJ B_NP cells_NNS was_VBD observed_VBN ._SENT Our_PP$ data_NNS point_VBP out_RP the_DT potency_NN of_IN systemic_JJ neutralizing_VBG Abs_NP against_IN both_DT free_JJ virus_NN and_CC virus-infected_JJ cells_NNS in_IN LNs_NP and_CC mucosa_NN and_CC demonstrate_VB the_DT protective_JJ effect_NN of_IN passive_JJ immunization_NN in_IN the_DT early_JJ phases_NNS of_IN retroviral_JJ infection_NN ._SENT In_IN viral_JJ infections_NNS ,_, neutralizing_VBG Abs_NP that_WDT inhibit_VBP attachment_NN to_TO the_DT host_NN cell_NN membrane_NN are_VBP naturally_RB generated_VBN after_IN infection_NN against_IN viral_JJ surface_NN proteins_NNS such_JJ as_IN Env_NP (_( for_IN a_DT review_NN see_VBP reference_NN )_) ._SENT Such_JJ neutralizing_VBG Abs_NP not_RB only_RB protect_VB the_DT host_NN from_IN reinfection_NN by_IN released_VBN virus_NN but_CC also_RB ,_, as_RB has_VBZ been_VBN conclusively_RB shown_VBN ,_, act_NN in_IN infected_JJ cells_NNS by_IN blocking_VBG virus_NN uncoating_NN ,_, virus_NN replication_NN ,_, release_NN of_IN infective_JJ viral_JJ particles_NNS ,_, chronic_JJ infection_NN ,_, and_CC cell-to-cell_NN transmission_NN of_IN the_DT virus_NN ._SENT We_PP demonstrate_VBP in_IN this_DT study_NN that_IN antibody_NN treatment_NN completely_RB prevents_VBZ chronic_JJ infection_NN in_IN lymphoid_JJ and_CC epithelial_JJ tissues_NNS and_CC that_IN even_RB tough_JJ initial_JJ infection_NN of_IN the_DT natural_JJ MMTV_NP targets_NNS ,_, DC_NP and_CC B_NP cells_NNS ,_, is_VBZ not_RB prevented_VBN ._SENT In_IN previous_JJ studies_NNS immunization_NN of_IN mice_NNS with_IN inactivated_VBN MMTV_NP ,_, purified_VBD gp52_NN ,_, or_CC synthetic_JJ Env_NP peptides_NNS failed_VBD to_TO prevent_VB SAg-induced_NP B-_NP and_CC T-cell_NN responses_NNS after_IN MMTV_NP infection_NN ,_, whereas_IN passive_JJ immunization_NN with_IN anti-SAg_NP MAbs_NP reduced_VBD the_DT SAg_NP response_NN ._SENT It_PP has_VBZ been_VBN suggested_VBN that_IN polyclonal_JJ anti-MMTV_NP Env_NP Abs_NP also_RB act_VB in_IN the_DT postinfection_NN phase_NN by_IN blocking_VBG the_DT SAg_NP response_NN ._SENT Although_IN these_DT results_NNS would_MD partly_RB explain_VB the_DT mechanism_NN of_IN MAb_NP 2B3_NP ,_, our_PP$ observations_NNS that_DT administration_NN of_IN MAb_NP 48_CD h_NN after_IN MMTV_NP infection_NN did_VBD not_RB prevent_VB the_DT SAg-induced_JJ T-cell_NN stimulation_NN argue_VBP against_IN this_DT hypothesis_NN ._SENT These_DT data_NNS are_VBP in_IN agreement_NN with_IN previous_JJ studies_NNS demonstrating_VBG that_DT zidovudine_NP (_( AZT_NP )_) treatment_NN 48_CD h_NN after_IN MMTV_NP infection_NN was_VBD incapable_JJ in_IN blocking_VBG virus_NN amplification_NN and_CC chronic_JJ infection_NN in_IN the_DT differentiated_VBN infected_JJ B_NN cells_NNS ._SENT Similar_JJ to_TO results_NNS of_IN our_PP$ present_JJ study_NN ,_, AZT_NP treatment_NN 24_CD h_NN after_IN virus_NN injection_NN induced_VBD only_RB partial_JJ inhibition_NN ._SENT Most_RBS likely_JJ the_DT first_JJ round_NN of_IN infection_NN is_VBZ not_RB completed_VBN after_IN 24_CD h._NN In_IN other_JJ virus_NN systems_NNS passively_RB transferred_VBN Abs_NP have_VBP been_VBN shown_VBN to_TO eradicate_VB early_JJ virus_NN dissemination_NN but_CC are_VBP inefficient_JJ late_RB in_IN infection_NN ._SENT It_PP is_VBZ generally_RB accepted_VBN that_IN higher_JJR neutralization_NN titers_NNS are_VBP required_VBN to_TO block_VB direct_JJ cell-to-cell_NN spread_VBN than_IN to_TO neutralize_VB infection_NN by_IN free_JJ virus_NN ._SENT This_DT explains_VBZ why_WRB passive_JJ immunization_NN after_IN infection_NN is_VBZ less_RBR efficient_JJ ._SENT It_PP has_VBZ previously_RB been_VBN shown_VBN that_IN infected_JJ lymphocytes_NNS can_MD produce_VB MMTV_NP particles_NNS ,_, but_CC the_DT role_NN of_IN these_DT released_VBN virus_NN particles_NNS in_IN chronic_JJ infection_NN is_VBZ debatable_JJ ._SENT Due_JJ to_TO the_DT absence_NN of_IN any_DT neutralizing_VBG effect_NN when_WRB the_DT MAb_NP was_VBD administered_VBN 48_CD h_NN after_IN virus_NN injection_NN ,_, it_PP is_VBZ unlikely_JJ that_IN free_JJ virus_NN plays_VBZ a_DT role_NN during_IN the_DT late_JJ phases_NNS of_IN infection_NN ._SENT Since_IN natural_JJ MMTV_NP infection_NN occurs_VBZ by_IN gradual_JJ delivery_NN of_IN MMTV_NP through_IN the_DT physiological_JJ oral_JJ route_NN to_TO PP_NP ,_, we_PP tested_VBD the_DT ability_NN of_IN parenterally_RB administered_VBN anti-Env_NP Abs_NP to_TO prevent_VB mucosal_JJ MMTV_NP infection_NN ._SENT The_DT present_JJ data_NNS show_VBP the_DT striking_JJ capacity_NN of_IN a_DT single_JJ low_JJ dose_NN of_IN 2B3_JJ IgG_NP given_JJ i.p._NN to_TO inhibit_VB SAg-induced_JJ T-cell_NN stimulation_NN in_IN the_DT NALT_NP ._SENT As_RB for_IN the_DT draining_VBG LN_NP ,_, the_DT data_NNS suggest_VBP that_IN systemic_JJ IgG_NP gains_NNS access_NN to_TO mucosal_JJ tissue_NN to_TO counter_VB MMTV_NP ._SENT This_DT is_VBZ in_IN agreement_NN with_IN previous_JJ reports_NNS indicating_VBG that_IN systemic_JJ virally_NNS induced_VBD IgG_NP can_MD protect_VB against_IN viral_JJ infection_NN at_IN the_DT mucosal_JJ surface_NN ._SENT In_IN contrast_NN to_TO results_NNS for_IN nasal_JJ infection_NN of_IN adult_NN mice_NNS ,_, only_RB a_DT partial_JJ protection_NN was_VBD observed_VBN in_IN PP_NP of_IN newborn_JJ mice_NNS when_WRB 10_CD mug_NN of_IN Abs_NP was_VBD administered_VBN ._SENT The_DT discrepancy_NN between_IN the_DT effects_NNS of_IN MAb_NP 2B3_JJ on_IN NALT_NP and_CC PP_NP infection_NN is_VBZ unlikely_JJ to_TO be_VB a_DT result_NN of_IN higher_JJR virus_NN load_NN in_IN the_DT pups_NNS (_( up_RB to_TO 1012_CD viral_JJ particles/ml_NN )_) since_IN infection_NN levels_NNS in_IN the_DT neonatal_JJ PP_NP are_VBP not_RB higher_JJR than_IN those_DT in_IN adult_NN draining_VBG LNs_NP ._SENT Most_RBS likely_RB ,_, the_DT accessibility_NN of_IN PP_NP for_IN systemic_JJ Abs_NP is_VBZ highly_RB restricted_VBN ._SENT The_DT accessibilities_NNS of_IN Abs_NP to_TO NALT_NP and_CC PP_NP are_VBP different_JJ ,_, since_IN most_RBS subepithelial_JJ capillaries_NNS in_IN the_DT mouse_NN PP_NP dome_NN ,_, unlike_IN those_DT in_IN villi_NNS ,_, lack_VBP endothelial_JJ fenestrae_NNS and_CC the_DT dome_NN capillary_NN network_NN is_VBZ less_RBR permeable_JJ to_TO macromolecules_NNS ._SENT The_DT late_JJ step_NN of_IN MMTV_NP infection_NN is_VBZ characterized_VBN by_IN the_DT systemic_JJ spread_NN of_IN the_DT virus_NN followed_VBN by_IN peripheral_JJ deletion_NN of_IN the_DT CD4+_NP T-cell_NN population_NN expressing_VBG the_DT appropriate_JJ T-cell_NN receptor_NN ,_, Vbeta_NP ._SENT In_IN this_DT study_NN no_DT deletion_NN of_IN Vbeta6+_NP T_NN cells_NNS in_IN MAb_NP 2B3-immunized_JJ mice_NNS 4_CD months_NNS after_IN infection_NN or_CC in_IN pups_NNS from_IN MAb_NP 2B3-treated_JJ infected_JJ mice_NNS ,_, even_RB after_IN three_CD litters_NNS ,_, was_VBD observed_VBN ._SENT It_PP has_VBZ been_VBN recently_RB demonstrated_VBN that_IN IgG_NP immune_JJ complexes_NNS can_MD activate_VB B_NP cells_NNS by_IN binding_VBG to_TO both_DT IgM_NP and_CC MyD88-dependent_JJ Toll-like_JJ receptors_NNS (_( TLR_NP )_) on_IN B_NP cells_NNS ._SENT TLR4_NP has_VBZ recently_RB been_VBN shown_VBN to_TO act_VB as_IN a_DT receptor_NN for_IN MMTV_NP ._SENT Absence_NN of_IN TLR4_NP binding_NN ,_, for_IN example_NN ,_, could_MD lead_VB to_TO the_DT absence_NN of_IN B-cell_NN activation_NN ._SENT It_PP is_VBZ likely_JJ that_IN in_IN passively_RB immunized_VBN infected_JJ mice_NNS the_DT majority_NN of_IN viral_JJ particles_NNS enter_VBP B_NP cells_NNS as_IN immune_JJ complexes_NNS coated_VBN with_IN neutralizing_VBG Abs_NP ._SENT This_DT explains_VBZ why_WRB the_DT virus_NN amplification_NN loop_NN in_IN B_NP cells_NNS could_MD be_VB abolished_VBN ._SENT In_IN agreement_NN with_IN this_DT interpretation_NN preexisting_VBG neutralizing_VBG Abs_NP inhibited_VBD B-cell_NN proliferation_NN and_CC differentiation_NN in_IN the_DT draining_VBG popliteal_JJ LN_NP 6_CD days_NNS after_IN MMTV_NP infection_NN ._SENT Intriguingly_RB ,_, differentiation_NN into_IN large_JJ CD138+_NP B220low_NP MHC-II+_NP B_NP cells_NNS was_VBD completely_RB blocked_VBN in_IN mice_NNS that_WDT were_VBD treated_VBN with_IN MAb_NP 2B3_JJ prior_RB to_TO MMTV_NP infection_NN ._SENT Moreover_RB ,_, MAb_NP 2B3_NP was_VBD able_JJ to_TO prevent_VB the_DT generation_NN of_IN neutralizing_VBG B-cell_NN memory_NN responses_NNS by_IN the_DT host_NN since_IN the_DT mice_NNS were_VBD fully_RB susceptible_JJ to_TO challenge_VB with_IN MMTV_NP SW_NP 2_CD months_NNS after_IN 2B_JJ 